Mammalian Transient and Stable Expression

High throughput processes (up to 1,000 Ab/day) with up to 3 step automated purification is perfect for large scale screening from AI-based designs. WuXian Transient provides high yield, high quality protein suitable for animal studies and other critical lead molecule assessment projects. WuXian TM Transient Platform

Popular Packages

Reference Yield

Timeline

QC

96 x 0.8 mL 24 x 3 mL

100-800 ug 0.5-2 mg

2 weeks 2-3 weeks 2-3 weeks

A280, Caliper (R/NR), and SEC-HPLC

20 mL

3-10 mg, average 4.5 mg after 2 step purification

<0.5 EU/mg endotoxin control, QC incl. Titer, A280, Caliper (R/NR) or SDS-PAGE, SEC-HPLC

400-1000 mg RP-HPLC, bioburden, DSF, DSC, SPR, LC/MS, SEC-MALS, peptide mapping, glycan profiling, cIEF, CHO HCP, residual DNA, ELISA, Western blot, freeze thaw study, micro-developability testing 3 weeks

1 L Additional QC

WuXian TM Express Platform

If you need more than a few grams of protein (e.g., developability studies), stable pool expression via the WuXian Express Platform is ideal. Our stable pool easily produces high quantity and quality protein in 5-6 weeks in shaker flask, wavebag or bioreactor.

Popular Packages

Reference Yield

Timeline

QC

<0.5 EU/mg endotoxin control, QC incl. Titer, A280, Caliper (R/NR) or SDS-PAGE, SEC-HPLC

20 mL

20 mg

2-3 weeks

1 L - 25 L Additional QC

1 - 25 gram RP-HPLC, bioburden, DSF, DSC, SPR, LC/MS, SEC-MALS, peptide mapping, glycan profiling, cIEF, CHO HCP, residual DNA, ELISA, Western blot, freeze thaw study, micro-developability testing 6-7 weeks

Comparable Product Quality of Different Scales

cIEF

GLYCAN

SEC_LC

SDS_CALIPER

100

100

0 20 40 60 80

0 20 40 60 80

50

50

0

0

Main Peak (%) HMW (%)

LMW (%)

200 L 1st-2000 L 2nd-2000 L Main Peak (%) Acidic Species (%) Basic Species (%)

200 L 1st-2000 L 2nd-2000 L G0 G0F Man5 G1F G2F

NR

R

200 L 1st-2000 L 2nd-2000 L

200 L 1st-2000 L 2nd-2000 L

Similar product quality is observed among different scales of WuXian Express (one transfection)

Learn more: Protein Sciences: Early-stage R&D Mammalian Platform

About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world’s leading global single-source platform from concept to commercialization.

wuxibiologics.com | info@wuxibiologics.com

2-7-2023

Powered by